This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Mar;10(2):99-100.

doi: 10.1007/s11912-008-0016-9.

Randomized trial of bevacizumab in advanced renal cell carcinoma

Ronald M Bukowski

PMID: 18377821
DOI: 10.1007/s11912-008-0016-9

Comment

Randomized trial of bevacizumab in advanced renal cell carcinoma

Ronald M Bukowski. Curr Oncol Rep. 2008 Mar.

. 2008 Mar;10(2):99-100.

doi: 10.1007/s11912-008-0016-9.

Author

Ronald M Bukowski

PMID: 18377821
DOI: 10.1007/s11912-008-0016-9

No abstract available

PubMed Disclaimer

Comment on

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D. Bukowski RM, et al. J Clin Oncol. 2007 Oct 10;25(29):4536-41. doi: 10.1200/JCO.2007.11.5154. Epub 2007 Sep 17. J Clin Oncol. 2007. PMID: 17876014 Clinical Trial.

References

1. N Engl J Med. 2003 Jul 31;349(5):427-34 - PubMed
1. J Clin Oncol. 2004 Dec 15;22(24):4991-5004 - PubMed
1. J Clin Oncol. 2005 Nov 1;23(31):7889-96 - PubMed
1. J Clin Oncol. 2007 Oct 10;25(29):4536-41 - PubMed

Publication types

Actions